Table 4 Comparison of platinum group vs. non – platinum group
Characteristics | Platinum Group (%) | Non-Platinum Group (%) | P value |
|---|---|---|---|
Total Number | 177 | 66 | Â |
Median age, years (range) | 58 (range 26–81) | 64 (range 29–80) | 0.003 |
Sex | Â | Â | 0.247 |
   Male | 112 (63.3) | 47 (71.2) |  |
   Female | 65 (36.7) | 19 (28.8) |  |
ECOG performance status at baseline | Â | Â | 0.047 |
   0 – 1 | 161 (91.0) | 54 (81.8) |  |
   ≥ 2 | 16 (9.0) | 12 (18.2) |  |
Disease | Â | Â | 0.361 |
   Intrahepatic cholangiocarcinoma | 72 (40.7) | 20 (30.3) |  |
   Gallbladder cancer | 51 (28.8) | 20 (30.3) |  |
   Extrahepatic bile duct cancer | 38 (21.5) | 22 (22.2) |  |
   Ampulla of Vater carcinoma | 16 (9.0) | 5 (7.6) |  |
Relapsed disease | 62 (35.0) | 22 (33.3) | 0.805 |
Biliary stent or bypass during treatment | 46 (26.0) | 18 (27.3) | 0.84 |
Disease associated infection during treatment (cholangitis, liver abscess) | 43 (24.3) | 19 (28.8) | 0.475 |
Duration from off chemotherapy to death | 3.3 months (95% CI, 2.6–3.9) | 4.0 months (95% CI, 2.6–5.5) | 0.071 |